Darolutamide does not interfere with OATP‐mediated uptake of docetaxel

The addition of darolutamide, an androgen receptor signalling inhibitor, to therapy with docetaxel has recently been approved as a strategy to treat metastatic prostate cancer. OATP1B3 is an SLC transporter that is highly expressed in prostate cancer and is responsible for the accumulation of substr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2024-07, Vol.155 (2), p.314-323
Hauptverfasser:	Buck, Stefan A. J., Talebi, Zahra, Drabison, Thomas, Jin, Yan, Gibson, Alice A., Hu, Peng, Bruijn, Peter, Ridder, Corrina M. A., Stuurman, Debra, Hu, Shuiying, Weerden, Wytske M., Koolen, Stijn L. W., Wit, Ronald, Sparreboom, Alex, Mathijssen, Ron H. J., Eisenmann, Eric D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen receptors Biomarkers cabazitaxel Cancer therapies Clinical outcomes darolutamide docetaxel Drug interaction In vitro Metastases Metastasis OATP Pharmacokinetics Prostate cancer Tumors Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!